Message01 Kensuke Egashira
Academic drug discovery: Academic drug discovery was established in the U.S.; drug-discovery ventures refine academia research results and transfers them to pharmaceutical companies that conduct a genuinely clinical development, an application and sales. Actually, about 60% of new drugs in the U.S. that have been approved by FDA are developed from academic drug discovery. On the other hand, in Japan, drug discovery capabilities have been delayed due to stagnation of drug discovery from academia. The greatest reason for stagnation of drug discovery from academia is because that venture companies playing a key role in incubating research achievements of universities have not been set. For putting the results of basic research to practical use, it is necessary for venture companies to continuously support “applied research” in academia. The research covers from target selection of drug discovery to preclinical studies. From this point of view, the role that drug discovery venture companies is important in academic drug discovery.